1. Podolsky DK. Inflammatory bowel disease. N Engl J Med 2002;347:417-429.
2. Frøslie KF, Jahnsen J, Moum BA, Vatn MH; IBSEN Group. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology 2007;133:412-422.
3. Schoepfer AM, Beglinger C, Straumann A, Trummler M, Renzulli P, Seibold F. Ulcerative colitis: correlation of the Rachmilewitz endoscopic activity index with fecal calprotectin, clinical activity, C-reactive protein, and blood leukocytes. Inflamm Bowel Dis 2009;15:1851-1858.
4. D’Haens G, Ferrante M, Vermeire S, et al. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease. Inflamm Bowel Dis 2012;18:2218-2224.
8. Väänänen P, Tenhunen R. Rapid immunochemical detection of fecal occult blood by use of a latex-agglutination test. Clin Chem 1988;34:1763-1766.
9. Kusaka T, Nozaki T, Shibata M, et al. Basic measurement performance evaluation of fecal occult blood analyzer OC sensor PLEDIA. J Clin Lab Instru Reagents 2014;3:643-648.
10. Wong WM, Lam SK, Cheung KL, et al. Evaluation of an automated immunochemical fecal occult blood test for colorectal neoplasia detection in a Chinese population. Cancer 2003;97:2420-2424.
11. Morikawa T, Kato J, Yamaji Y, Wada R, Mitsushima T, Shiratori Y. A comparison of the immunochemical fecal occult blood test and total colonoscopy in the asymptomatic population. Gastroenterology 2005;129:422-428.
12. van der Vlugt M, Grobbee EJ, Bossuyt PM, et al. Interval colorectal cancer incidence among subjects undergoing multiple rounds of fecal immunochemical testing. Gastroenterology 2017;153:439-447.e2.
13. Vilkin A, Rozen P, Levi Z, et al. Performance characteristics and evaluation of an automated-developed and quantitative, immunochemical, fecal occult blood screening test. Am J Gastroenterol 2005;100:2519-2525.
14. Guittet L, Guillaume E, Levillain R, et al. Analytical comparison of three quantitative immunochemical fecal occult blood tests for colorectal cancer screening. Cancer Epidemiol Biomarkers Prev 2011;20:1492-1501.
15. Catomeris P, Baxter NN, Boss SC, et al. Effect of temperature and time on fecal hemoglobin stability in 5 fecal immunochemical test methods and one guaiac method. Arch Pathol Lab Med 2018;142:75-82.
18. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis: a randomized study. N Engl J Med 1987;317:1625-1629.
19. Senju O, Takagi Y, Uzawa R, et al. A new immuno quantitative method by latex agglutination: application for the determination of serum C-reactive protein (CRP) and its clinical significance. J Clin Lab Immunol 1986;19:99-103.
20. Martinuzzo ME, Ujhelly C, Barrera LH, et al. Validation of an automated immunoturbidimetric assay for fibrinogen/fibrin degradation products measurement and its correlation to a semi-quantitative latex agglutination test. Clin Lab 2016;62:2085-2089.
23. Nancey S, Boschetti G, Moussata D, et al. Neopterin is a novel reliable fecal marker as accurate as calprotectin for predicting endoscopic disease activity in patients with inflammatory bowel diseases. Inflamm Bowel Dis 2013;19:1043-1052.
24. Ma C, Lumb R, Walker EV, et al. Noninvasive fecal immunochemical testing and fecal calprotectin predict mucosal healing in inflammatory bowel disease: a prospective cohort study. Inflamm Bowel Dis 2017;23:1643-1649.
25. Inoue K, Aomatsu T, Yoden A, Okuhira T, Kaji E, Tamai H. Usefulness of a novel and rapid assay system for fecal calprotectin in pediatric patients with inflammatory bowel diseases. J Gastroenterol Hepatol 2014;29:1406-1412.
26. Okuyama Y, Doi Y, Matsuyama N, Uchino M, Yamamoto T. A novel sol particle immunoassay for fecal calprotectin in inflammatory bowel disease patients. Clin Chim Acta 2016;456:1-6.
28. Heida A, Knol M, Kobold AM, Bootsman J, Dijkstra G, van Rheenen PF. Agreement between home-based measurement of stool calprotectin and ELISA results for monitoring inflammatory bowel disease activity. Clin Gastroenterol Hepatol 2017;15:1742-1749.e2.
29. Bello C, Roseth A, Guardiola J, et al. Usability of a home-based test for the measurement of fecal calprotectin in asymptomatic IBD patients. Dig Liver Dis 2017;49:991-996.
30. Puolanne AM, Kolho KL, Alfthan H, Ristimäki A, Mustonen H, Färkkilä M. Rapid faecal tests for detecting disease activity in colonic inflammatory bowel disease. Eur J Clin Invest 2016;46:825-832.